Company: SPEG
Filing Date: 2025-01-21
Form Type: CORRESP
Source: 0001213900-25-005100
Chunk: 1

Company: Silver Pegasus Acquisition Corp.
Filing Date: 2025-01-21
Form: CORRESP
Chunk 1
---
 the founders shares. State whether the securities issuances may result in a material dilution of the purchasers’ equity interests as required by Item 1602(a)(3) of Regulation S-K. Provide a cross-reference, highlighted by prominent type or in another manner, to the locations of related disclosures in the prospectus.

Response: The Company revised
the disclosure in the S-1 to address the Staff’s comment. Please see the revised Cover Page of the S-1.

3. In the paragraph where you disclose conflicts of interest, please provide a cross reference, highlighted by prominent type or in another manner, to the locations of related disclosures in the prospectus, as required by Item 1602(a)(5) of Regulation S-K of the S-1.

Response: The Company revised
the disclosure in the S-1 to address the Staff’s comment. Please see the revised Cover Page of the S-1.

4. We note your disclosure that 100% of the units, including the overallotment may be sold to non-managing sponsor investors. Please disclose whether there is a cap on the amount that each investor may purchase. Please disclose that the non-managing sponsor investors will have the potential to realize enhanced economic returns from their investment as compared to other investors purchasing in the offering. Please revise the summary to further clarify the potential impact such purchases could have upon the trading volume, volatility and liquidity. Additionally, please clarify all impacts of these sales on public investors and please tell us whether the limited number of public investors could impact the company’s listing eligibility. Please provide appropriate risk factor disclosure, including the potential conflicts of interest with the non-managing sponsor investors in approving your business combination and otherwise exercising their rights as public shareholders because of their indirect ownership of founder shares and private placement units. Lastly, please file the form of any agreements with the non-managing sponsor investors as exhibits.

Response: The Company
revised the disclosure in the S-1 to address the Staff’s comment. Please see the revised Cover Page and pages 24, 145 and 184. Please
also see Risk Factors “Potential participation in this offering by our non-managing sponsor investors could reduce the public float for our securities”on page 77 and “Since our sponsor, officers and directors and any other holder of our founder shares, including any non-managing sponsor investors will lose their entire investment in us if our initial business combination is not completed (other than with respect to any public shares they may acquire during or after this offering), and because